• Bextra®
• Alert
• Alternative
• Attorney
• Claim
• Class Action
• Complications
• Danger
• Depression
• Dosage
• Effects
• Heart
• Information
• Injury
• Lawsuit
• Litigation
• Medication
• Problems
• Reaction
• Recall
• Risks
• Safety
• Stroke
• Warnings
• Contact a Lawyer

Find a Lawyer in Your State

Need Help?

• Accutane®
• Cerebral Palsy
• Darvocet®
• Denture Cream
• Depuy ASR™ Hip Implant
• Fosamax® Femur Fracture
• MiniMed Insulin Pump
• Multaq®
• Nephrogenic Systemic Fibrosis
• Paxil® Birth Defects
• Propecia®
• Shoulder Pain Pump
• Topamax®
• Truck Accident Lawyer
• Wellbutrin®
• Yaz® Birth Control

Concerns about Bextra® stroke risks have been mounting ever since a similar drug, named Vioxx®, was recalled. Vioxx® was voluntarily recalled in September 2004 after clinical studies proved that taking this pain medication significantly increases a person''s risk of stroke or heart problems. Bextra® and Vioxx® are both non-steroidal anti-inflammatory prescription medications that are used to treat the debilitating pain associated with osteoarthritis, rheumatoid arthritis, and severe menstrual cramps.

Bextra® is manufactured by Pfizer and was approved by the FDA in November 2001. There are a number of common and more serious side effects associated with taking this medication. Common side effects of Bextra® include indigestion, headache, stomach pain, nausea, and diarrhea. More serious side effects associated with taking Bextra® can include: anaphylactic or allergic reaction and serious skin conditions, such as Stevens - Johnson syndrome and toxic epidermal necrolysis.

The risk of developing skin conditions associated with Bextra® is so strong that the FDA is considering requiring a black box warning on all Bextra® product packaging information. The black box warning is the strongest cautionary device utilized by the Food and Drug administration.

In addition to the risks of the aforementioned side effects, worry about Bextra® stroke and heart attack risks has now taken center stage with regards to the safety of this COX-2 selective pain reliever. At the annual American Heart Association conference in New Orleans in October 2004, a leading heart researcher presented evidence that Bextra® stroke and heart attack risks were greater than the risk of these serious events in the general population. This expert stated that Bextra® stroke and heart attack risks might even pose a greater threat than Vioxx® to human health.

This evidence swiftly became national headline news after being published in a New York Times article and a number of subsequent syndications. Pfizer quickly issued a public statement, claiming that evidence of Bextra® stroke and heart attack risks is unsubstantiated and has not been officially confirmed in medical journals or by independent research.

While this may be true, it does not preclude any potential Bextra® stroke and heart risks that may accompany Bextra® use. Both the FDA and Pfizer have announced plans to conduct further research to determine Bextra® stroke and heart attack risks. In the meantime, it is important that patients concerned about Bextra® stroke first speak to their doctor before making any changes to their treatment.

Symptoms of a Bextra® stroke might include any of the following: numbness or weakness in the arms, face, or legs (especially on one side of the body), confusion, trouble speaking or understanding others, visual disturbances, dizziness, loss of balance or coordination, and a sudden severe headache.

If you are concerned about Bextra® stroke or have experienced any of these Bextra® stroke symptoms you may wish to speak to a medical professional as soon as possible.

"Bextra Suit Filed"

Bextra , the popular cox-2 inhibitor recalled by Pfizer, is the subject of another lawsuit.

Rita Fohne has filed her lawsuit against Pfizer in Madison County, Illinois, seeking ...

» Read More

"FDA issues drug warnings on its Web site"

The U.S. Food and Drug Administration has started issuing alerts to patients and doctors on its new site Drug Watch. Including emerging drug-safety concerns, as well as dangers presented by drugs prescribed for unapproved uses, the new site is in resp...

» Read More

"FDA to listen to outside advisers in hopes of improving drug-monitoring system"

After a controversial year of drug recalls, the FDA was under attack for failing to adequately protect consumers from dangerous drugs. Currently, the FDA has the Adverse Event Reporting System, or AERS, to collect voluntary reports of possible reactio...

» Read More

• Accutane® |
• Acetaminophen |
• Actavis Information |
• Actos® |
• Amiodarone |
• Trasylol® - Aprotinin Injection |
• Avandia® |
• Baycol® |
• Bextra® |
• Botox |
• Byetta® |
• Celebrex |
• Cellcept |
• Chantix® |
• Cipro Side Effects |
• Crestor |
• Darvocet |
• Darvon® |
• Defective Drug FAQ |
• Common Defective Drugs |
• Depakote® |
• Drug Company Information |
• Defective Drug Side Effects |
• Duragesic Patch |
• Exjade |
• Fentanyl |
• Fen Phen |
• Fleet Phospho Soda |
• Fluoroquinolone Antibiotics |
• Fosamax |
• Gadolinium |
• Gardasil |
• Gleevec |
• Heparin |
• Humira and Remicade |
• Hydroquinone |
• Hydroxycut |
• Januvia® and Janumet® Information |
• Kava Kava |
• Ketek |
• Lariam |
• Levaquin |
• Lupron (Leuprolide) |
• Meridia |
• Multaq® |
• Naproxen (Aleve) |
• Natrecor |
• Neurontin |
• Nexium® (Esomeprazole Magnesium) Heartburn Relief |
• NuvaRing® |
• Ocella Information |
• Osteonecrosis and Fosamax |
• Oxycontin |
• Palladone |
• Paxil |
• Permax |
• Plavix |
• PPA |
• Pradaxa® |
• Prevacid® |
• Prilosec® |
• Procrit |
• Propecia® (Finasteride) |
• Propoxyphene |
• Protonix® |
• Protopic |
• Prozac |
• What is Quinine? |
• Rapamune® Lawyer |
• Raptiva |
• Reglan |
• Remicade Lawsuit |
• Rezulin |
• Risperdal |
• Ritalin |
• Serevent |
• Seroquel |
• Serzone |
• Tequin |
• Thimerosal |
• Topamax® (Topiramate) |
• Viagra® |
• Wellbutrin® |
• Xenical |
• Yasmin® |
• Yaz Birth Control Lawyer |
• Zelnorm |
• Zocor® Medication Information |
• Zoloft |
• Zyprexa |